Identification

Name
Fluticasone propionate
Accession Number
DB00588  (APRD00065)
Type
Small Molecule
Groups
Approved
Description

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Structure
Thumb
Synonyms
Not Available
External IDs
CCI 18781 / CCI-18781 / PF-00241939
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aermony RespiclickPowder, metered232 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
Aermony RespiclickPowder, metered55 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
Aermony RespiclickPowder, metered113 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
ArmonAir RespiClickPowder, metered55 ug/1Respiratory (inhalation)Teva Respiratory, LLC2017-08-07Not applicableUs
ArmonAir RespiClickPowder, metered113 ug/1Respiratory (inhalation)Teva Respiratory, LLC2017-08-07Not applicableUs
ArmonAir RespiClickPowder, metered232 ug/1Respiratory (inhalation)Teva Respiratory, LLC2017-08-07Not applicableUs
CutivateLotion.5 mg/mLTopicalPharma Derm, A Division Of Nycomed Us Inc.2009-10-05Not applicableUs
CutivateCream0.05 %TopicalGlaxosmithkline Inc2004-11-082013-08-01Canada
CutivateLotion.5 mg/mLTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2009-10-05Not applicableUs
CutivateCream.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1990-12-18Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluticasoneSpray, metered50 mcgNasalApotex Corporation2007-07-05Not applicableCanada
FluticasoneSpray, metered50 ug/1NasalMesource Pharmaceuticals2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalUnit Dose Services2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalMorton Grove Pharmaceuticals, Inc.2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalDirectrx2014-01-01Not applicableUs
FluticasoneSpray, metered50 ug/1NasalUnit Dose Services2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalNu Care Pharmaceuticals,inc.2012-01-09Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalApotex Corporation2007-09-19Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalPhysicians Total Care, Inc.2006-03-08Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalBlenheim Pharmacal, Inc.2007-09-19Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour Allergy NasalSpray, metered50 ug/1NasalShopko Stores Operating2016-08-23Not applicableUs
24 Hour Allergy NasalSpray, metered50 ug/1NasalHyvee2016-08-08Not applicableUs
24 Hour Allergy NasalSpray, metered50 ug/1NasalWalgreen2016-05-27Not applicableUs
24 Hour Allergy Relief NasalSpray, metered50 ug/1NasalMeijer Distribution2016-11-17Not applicableUs
24 Hour Allergy Relief nasalSpray, metered50 ug/1NasalKroger2016-05-27Not applicableUs
24hr Nasal Allergy ReliefSpray, metered50 mcgNasalApotex CorporationNot applicableNot applicableCanada
Allergy NasalSpray, metered50 ug/1NasalWalgreen2016-07-12Not applicableUs
Allergy ReliefSpray, metered50 ug/1NasalDiscount Drug Mart2017-07-03Not applicableUs
Allergy ReliefSpray, metered50 ug/1NasalMeijer Distribution2016-05-27Not applicableUs
Allergy Relief NasalSpray, metered50 ug/1NasalPublix Supermarkets, Inc.2016-09-08Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Exchange Select Allergy ReliefSpray, metered50 ug/1NasalArmy + Air Force Exchange Service2017-10-27Not applicableUs
International/Other Brands
Ezicas (Intas) / Flixonase (GlaxoSmithKline) / Flixotide (GlaxoSmithKline) / Flovent (GlaxoSmithKline) / FLOVENTHFA / Flunase (GlaxoSmithKline) / Nasofan (Teva) / Pirinase (GlaxoSmithKline) / Seretide (GlaxoSmithKline)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Advair 100 DiskusFluticasone propionate (100 mcg) + Salmeterol (50 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair 125Fluticasone propionate (125 mcg) + Salmeterol (25 mcg)Aerosol, meteredRespiratory (inhalation)Glaxosmithkline Inc2001-12-21Not applicableCanada
Advair 250Fluticasone propionate (250 mcg) + Salmeterol (25 mcg)Aerosol, meteredRespiratory (inhalation)Glaxosmithkline Inc2001-12-21Not applicableCanada
Advair 250 DiskusFluticasone propionate (250 mcg) + Salmeterol (50 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair 500 DiskusFluticasone propionate (500 mcg) + Salmeterol (50 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair DiskusFluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)Remedy Repack2016-07-272017-03-09Us
Advair DiskusFluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2001-02-28Not applicableUs
Advair DiskusFluticasone propionate (500 ug/1) + Salmeterol xinafoate (50 ug/1)PowderOral; Respiratory (inhalation)Physicians Total Care, Inc.2001-06-21Not applicableUs
Advair DiskusFluticasone propionate (500 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-02-17Not applicableUs
Advair DiskusFluticasone propionate (250 ug/1) + Salmeterol xinafoate (50 ug/1)PowderOral; Respiratory (inhalation)Dispensing Solutions, Inc.2001-02-05Not applicableUs
Categories
UNII
O2GMZ0LF5W
CAS number
80474-14-2
Weight
Average: 500.571
Monoisotopic: 500.184429407
Chemical Formula
C25H31F3O5S
InChI Key
WMWTYOKRWGGJOA-CENSZEJFSA-N
InChI
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
SMILES

Pharmacology

Indication

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.

Structured Indications
Pharmacodynamics

Fluticasone is an extremely potent vasoconstrictor and anti-inflammatory agent. Its effectiveness in inhaled forms is due to its direct local effect.

Mechanism of action

Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UProgesterone receptor
agonist
Human
UCytosolic phospholipase A2
inhibitor
Human
UMineralocorticoid receptor
antagonist
Human
Absorption

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Bioavailability, intranasal = <2%; Oral bioavailability is negligible and the major circulating entity is an inactive metabolite.

Volume of distribution

IV administration = 4.2 L/kg

Protein binding

91%

Metabolism

Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.

Route of elimination

Less than 5% of the oral dose was excreted in the urine as metabolites. The rest of the dose is excreted in the feces and parent drug and metabolites.

Half life

Terminal elimination half-life = 7.8 hours

Clearance

The total blood clearance of fluticasone propionate is high (average, 1,093 mL/min), with renal clearance accounting for less than 0.02% of the total.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluticasone propionate.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluticasone propionate.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fluticasone propionate.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Fluticasone propionate.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluticasone propionate.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluticasone propionate.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fluticasone propionate.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Fluticasone propionate.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fluticasone propionate.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Fluticasone propionate.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone propionate.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Fluticasone propionate can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fluticasone propionate.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluticasone propionate.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluticasone propionate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone propionate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluticasone propionate.Experimental
AprepitantThe serum concentration of Fluticasone propionate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluticasone propionate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluticasone propionate.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fluticasone propionate.Approved
AtazanavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fluticasone propionate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Fluticasone propionate.Investigational, Vet Approved
AzelastineFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluticasone propionate.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluticasone propionate.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Fluticasone propionate.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluticasone propionate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Fluticasone propionate.Approved
BoceprevirThe serum concentration of Fluticasone propionate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Fluticasone propionate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fluticasone propionate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fluticasone propionate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Fluticasone propionate.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluticasone propionate.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Fluticasone propionate.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluticasone propionate.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluticasone propionate.Approved, Investigational
BuprenorphineFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluticasone propionate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fluticasone propionate.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluticasone propionate.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fluticasone propionate.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluticasone propionate.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluticasone propionate.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluticasone propionate.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Fluticasone propionate.Investigational
CarbamazepineThe metabolism of Fluticasone propionate can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fluticasone propionate.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate.Approved
CeritinibThe serum concentration of Fluticasone propionate can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluticasone propionate.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluticasone propionate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluticasone propionate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluticasone propionate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluticasone propionate.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fluticasone propionate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluticasone propionate.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluticasone propionate.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Fluticasone propionate can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluticasone propionate can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fluticasone propionate.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Fluticasone propionate.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Fluticasone propionate.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluticasone propionate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Fluticasone propionate.Experimental
ClotrimazoleThe metabolism of Fluticasone propionate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fluticasone propionate.Approved
CobicistatThe serum concentration of Fluticasone propionate can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fluticasone propionate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluticasone propionate.Approved, Illicit
ConivaptanThe serum concentration of Fluticasone propionate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Fluticasone propionate can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone propionate.Approved
CyclosporineThe metabolism of Fluticasone propionate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Fluticasone propionate.Approved
DabrafenibThe serum concentration of Fluticasone propionate can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluticasone propionate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Fluticasone propionate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Fluticasone propionate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluticasone propionate can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Fluticasone propionate.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluticasone propionate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluticasone propionate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone propionate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluticasone propionate.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fluticasone propionate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fluticasone propionate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fluticasone propionate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone propionate.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Fluticasone propionate.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluticasone propionate.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluticasone propionate.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluticasone propionate.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Fluticasone propionate.Experimental
DihydroergotamineThe metabolism of Fluticasone propionate can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fluticasone propionate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fluticasone propionate.Experimental, Illicit
DiltiazemThe metabolism of Fluticasone propionate can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fluticasone propionate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fluticasone propionate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Fluticasone propionate.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluticasone propionate.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Fluticasone propionate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Fluticasone propionate.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved, Illicit
DronedaroneThe metabolism of Fluticasone propionate can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluticasone propionate.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluticasone propionate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluticasone propionate.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fluticasone propionate.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Fluticasone propionate.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluticasone propionate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluticasone propionate.Approved, Investigational
EnzalutamideThe serum concentration of Fluticasone propionate can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluticasone propionate.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluticasone propionate.Approved
ErythromycinThe metabolism of Fluticasone propionate can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluticasone propionate.Approved
EthanolFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluticasone propionate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Fluticasone propionate.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluticasone propionate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fluticasone propionate.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fluticasone propionate.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluticasone propionate.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluticasone propionate.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fluticasone propionate.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fluticasone propionate.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fluticasone propionate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Fluticasone propionate.Experimental
FluconazoleThe metabolism of Fluticasone propionate can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone propionate.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fluticasone propionate.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fluticasone propionate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone propionate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluticasone propionate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluticasone propionate.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Fluticasone propionate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fluticasone propionate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluticasone propionate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fluticasone propionate can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluticasone propionate.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Fluticasone propionate can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluticasone propionate.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Fluticasone propionate.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluticasone propionate.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluticasone propionate.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluticasone propionate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fluticasone propionate.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fluticasone propionate.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluticasone propionate.Approved
HydrocodoneFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluticasone propionate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Iloperidone.Approved
ImatinibThe metabolism of Fluticasone propionate can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluticasone propionate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Fluticasone propionate.Investigational
IsavuconazoniumThe metabolism of Fluticasone propionate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fluticasone propionate.Approved, Vet Approved
IsradipineThe metabolism of Fluticasone propionate can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluticasone propionate can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluticasone propionate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluticasone propionate.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Fluticasone propionate.Approved, Investigational
KetoconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone propionate.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluticasone propionate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fluticasone propionate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fluticasone propionate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluticasone propionate.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Fluticasone propionate.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fluticasone propionate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Fluticasone propionate.Illicit
LopinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Fluticasone propionate.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Fluticasone propionate.Approved
LovastatinThe metabolism of Fluticasone propionate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fluticasone propionate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone propionate.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Fluticasone propionate.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Fluticasone propionate.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Fluticasone propionate.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluticasone propionate.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fluticasone propionate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Fluticasone propionate.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluticasone propionate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Fluticasone propionate.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fluticasone propionate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Fluticasone propionate.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluticasone propionate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fluticasone propionate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluticasone propionate.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluticasone propionate.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluticasone propionate.Approved
MethotrimeprazineFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fluticasone propionate.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Fluticasone propionate.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluticasone propionate.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fluticasone propionate.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Fluticasone propionate.Approved
MetyrosineFluticasone propionate may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluticasone propionate.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone propionate.Approved, Illicit
MifepristoneThe serum concentration of Fluticasone propionate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved, Investigational
MirtazapineFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Fluticasone propionate can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fluticasone propionate.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fluticasone propionate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fluticasone propionate.Approved
NefazodoneThe serum concentration of Fluticasone propionate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fluticasone propionate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluticasone propionate can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Fluticasone propionate.Approved, Investigational
NilotinibThe metabolism of Fluticasone propionate can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluticasone propionate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluticasone propionate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Fluticasone propionate.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Fluticasone propionate.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Fluticasone propionate.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Fluticasone propionate.Approved, Investigational
OlaparibThe metabolism of Fluticasone propionate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fluticasone propionate.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Fluticasone propionate.Approved, Illicit
OrphenadrineFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fluticasone propionate.Investigational
OsimertinibThe serum concentration of Fluticasone propionate can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Fluticasone propionate.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fluticasone propionate.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluticasone propionate.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluticasone propionate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fluticasone propionate.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Fluticasone propionate can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fluticasone propionate.Approved
ParaldehydeFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Fluticasone propionate.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fluticasone propionate.Approved, Vet Approved
PentobarbitalThe metabolism of Fluticasone propionate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluticasone propionate.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Fluticasone propionate.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Fluticasone propionate.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fluticasone propionate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluticasone propionate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Fluticasone propionate.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Fluticasone propionate.Experimental
PhenobarbitalThe metabolism of Fluticasone propionate can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Fluticasone propionate.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fluticasone propionate.Approved
PhenytoinThe metabolism of Fluticasone propionate can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone propionate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluticasone propionate.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Fluticasone propionate.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluticasone propionate.Approved
PizotifenThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleFluticasone propionate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluticasone propionate.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluticasone propionate.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluticasone propionate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluticasone propionate.Approved
PrimidoneThe metabolism of Fluticasone propionate can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluticasone propionate.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluticasone propionate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Fluticasone propionate.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fluticasone propionate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fluticasone propionate.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone propionate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Fluticasone propionate.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fluticasone propionate.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluticasone propionate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone propionate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Fluticasone propionate.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Fluticasone propionate.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Fluticasone propionate can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluticasone propionate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluticasone propionate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fluticasone propionate.Approved, Investigational
RifabutinThe metabolism of Fluticasone propionate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluticasone propionate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluticasone propionate can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone propionate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Fluticasone propionate.Investigational
RitonavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluticasone propionate.Vet Approved
RopiniroleFluticasone propionate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluticasone propionate.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Fluticasone propionate.Approved
RotigotineFluticasone propionate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluticasone propionate.Approved
SaquinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluticasone propionate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Fluticasone propionate.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fluticasone propionate.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluticasone propionate.Approved, Vet Approved
SildenafilThe metabolism of Fluticasone propionate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluticasone propionate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluticasone propionate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fluticasone propionate.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
St. John's WortThe serum concentration of Fluticasone propionate can be decreased when it is combined with St. John&#39;s Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Fluticasone propionate can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone propionate.Approved, Investigational
SulfisoxazoleThe metabolism of Fluticasone propionate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fluticasone propionate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Fluticasone propionate.Experimental
SuvorexantFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Fluticasone propionate.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tasimelteon.Approved
TelaprevirThe serum concentration of Fluticasone propionate can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Fluticasone propionate can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Fluticasone propionate.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluticasone propionate.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluticasone propionate.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluticasone propionate.Investigational
ThalidomideFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluticasone propionate.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluticasone propionate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fluticasone propionate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Fluticasone propionate.Approved, Investigational
TiclopidineThe metabolism of Fluticasone propionate can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluticasone propionate.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Fluticasone propionate.Experimental
TipranavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Fluticasone propionate can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluticasone propionate.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Fluticasone propionate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluticasone propionate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fluticasone propionate.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluticasone propionate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluticasone propionate.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Fluticasone propionate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Fluticasone propionate.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluticasone propionate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Fluticasone propionate.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluticasone propionate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluticasone propionate.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Fluticasone propionate.Approved, Experimental
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluticasone propionate.Approved, Investigational
VenlafaxineThe metabolism of Fluticasone propionate can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Fluticasone propionate.Experimental
VerapamilThe metabolism of Fluticasone propionate can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Fluticasone propionate.Experimental
VoriconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fluticasone propionate.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Fluticasone propionate.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluticasone propionate.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluticasone propionate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Fluticasone propionate can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluticasone propionate.Vet Approved
ZolpidemFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluticasone propionate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Fluticasone propionate.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fluticasone propionate.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Joseph Kaspi, Oded Arad, Michael Brand, Moty Shookrun, Simona Malka, Mohammed Alnabari, Shalom Hazan, Vlado Malesevic, "Synthesis and powder preparation of fluticasone propionate." U.S. Patent US20060009435, issued January 12, 2006.

US20060009435
General References
Not Available
External Links
Human Metabolome Database
HMDB14726
KEGG Drug
D01708
PubChem Compound
444036
PubChem Substance
46506140
ChemSpider
392059
BindingDB
50354849
ChEBI
31441
ChEMBL
CHEMBL1473
Therapeutic Targets Database
DAP001039
PharmGKB
PA449686
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluticasone_propionate
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (159 KB)
MSDS
Download (39 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAsthma Bronchial1
1CompletedNot AvailablePulmonary Disease, Chronic Obstructive1
1CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Smoke-related Lung Diseases1
1CompletedDiagnosticAirway Inflammation1
1CompletedDiagnosticAllergic Rhinitis (AR)1
1CompletedScreeningPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentAllergic Rhinitis (AR)4
1CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
1CompletedTreatmentAsthma Bronchial4
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)3
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentMild to Moderate Asthma1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1RecruitingTreatmentVocal Fold Nodules1
2CompletedNot AvailableAsthma Bronchial1
2CompletedPreventionAllergic Rhinitis (AR)1
2CompletedPreventionCarcinoma, Bronchogenic1
2CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Seasonal2
2CompletedTreatmentAsthma Bronchial15
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)3
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentEsophagitis1
2CompletedTreatmentObliterative Bronchiolitis1
2CompletedTreatmentOesophagitis, Eosinophilic2
2CompletedTreatmentPulmonary Disease, Chronic Obstructive1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2Enrolling by InvitationTreatmentPolyps, Nasal1
2Not Yet RecruitingTreatmentAsthma Bronchial1
2RecruitingDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentAllergic Rhinitis (AR)1
2RecruitingTreatmentAsthma Bronchial2
2TerminatedPreventionBronchiectasis / Chronic Bronchitis / Pulmonary Diseases1
2TerminatedTreatmentAsthma Bronchial3
2TerminatedTreatmentBronchiolitis1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2WithdrawnNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
2WithdrawnTreatmentAsthma Bronchial1
2, 3Not Yet RecruitingTreatmentOesophagitis, Eosinophilic1
2, 3RecruitingTreatmentEosinophilic Esophagitis (EoE) / Eosinophilic Gastrointestinal Disorders (EGIDs)1
2, 3RecruitingTreatmentEosinophilic Gastrointestinal Disorders (EGIDs) / Oesophagitis, Eosinophilic1
3Active Not RecruitingTreatmentOesophagitis, Eosinophilic / Swallowing Disorders1
3CompletedNot AvailableAllergic Rhinitis (AR) / Seasonal Allergic Rhinitis (SAR)1
3CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
3CompletedPreventionStridor1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAsthma Bronchial25
3CompletedTreatmentBronchial Asthma1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)5
3CompletedTreatmentChronic Sinusitis With or Without Nasal Polyps1
3CompletedTreatmentChronic Sinusitis With or Without Nasal Polyps / Chronic Sinusitis: [Nos] or [Ethmoidal] or [Chronic Pansinusitis] or [Sphenoidal] / Polyps, Nasal1
3CompletedTreatmentExercised Induced Asthma1
3CompletedTreatmentOesophagitis, Eosinophilic1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)6
3Not Yet RecruitingTreatmentChronic Rhinosinustis With Polyps1
3RecruitingTreatmentAsthma Bronchial4
3RecruitingTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
3TerminatedPreventionAtopic Dermatitis (AD)1
3TerminatedTreatmentCroup1
3Unknown StatusNot AvailableSeasonal Allergic Rhinitis (SAR)1
3Unknown StatusTreatmentPulmonary Disease, Chronic Obstructive2
3WithdrawnTreatmentAsthma Bronchial1
3WithdrawnTreatmentBronchial Asthma1
3WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD)3
4Active Not RecruitingBasic ScienceHealthy Volunteers1
4CompletedNot AvailableAsthma Bronchial1
4CompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedBasic ScienceAsthma Bronchial1
4CompletedBasic ScienceAsthma Bronchial / Healthy Volunteers1
4CompletedBasic ScienceMild Asthma1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticAsthma, Allergic1
4CompletedDiagnosticAsthmatic Smokers / Non-asthmatic Smokers1
4CompletedPreventionAllergic Rhinitis (AR) / Conjunctivitis, Seasonal Allergic1
4CompletedTreatmentAllergic Rhinitis (AR)2
4CompletedTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
4CompletedTreatmentAsthma Bronchial29
4CompletedTreatmentAsthma Bronchial / Mild Asthma1
4CompletedTreatmentAsthmatic Patients1
4CompletedTreatmentAtopic Dermatitis (AD)4
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentBronchiectasis1
4CompletedTreatmentChronic Bronchitis / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)6
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Depressive State1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedTreatmentPersistent Asthma1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive3
4CompletedTreatmentRhinitis, Allergic, Perennial / Seasonal Allergic Rhinitis (SAR)2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentSkin Diseases1
4Enrolling by InvitationTreatmentAsthma Bronchial1
4Not Yet RecruitingTreatmentAllergic Rhinitis (AR) / Allergies / Asthma, Allergic1
4RecruitingBasic ScienceAllergic Rhinitis (AR)1
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAllergic Rhinitis (AR) / House Dust Mite Allergy1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentAsthmatic Bronchitis / Obstruction Airway / Wheezing / Wheezy Bronchitis1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentOesophagitis, Eosinophilic1
4RecruitingTreatmentPulmonary Disease, Chronic Obstructive2
4TerminatedTreatmentAsthma Bronchial2
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4TerminatedTreatmentRhinitis, Allergic, Perennial1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusTreatmentCream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo / Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05% / Patients With Active Non-segmental Vitiligo1
4Unknown StatusTreatmentOesophagitis, Eosinophilic1
4Unknown StatusTreatmentPercentage of Annual Acute Exacerbation / Quality of Life1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
4WithdrawnTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAsthma Bronchial8
Not AvailableCompletedNot AvailableAsthma Bronchial / Atopics1
Not AvailableCompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailablePulmonary Disease, Chronic Obstructive2
Not AvailableCompletedNot AvailableRespiratory Disorders2
Not AvailableCompletedNot AvailableRhinitis2
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal1
Not AvailableCompletedNot AvailableSmokers / Smoking1
Not AvailableCompletedNot AvailableTobacco Abuse Smoke1
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceSeasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedPreventionCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentAllergies1
Not AvailableCompletedTreatmentAsthma Bronchial2
Not AvailableCompletedTreatmentAsthma, Allergic / Mild Allergic Asthma1
Not AvailableCompletedTreatmentPolyp of Nasal Sinus1
Not AvailableCompletedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableCompletedTreatmentSuspected Eosinophilic Esophagitis1
Not AvailableNot Yet RecruitingNot AvailableAsthma Bronchial1
Not AvailableNot Yet RecruitingDiagnosticChildhood Asthma1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableRecruitingNot AvailableBronchiolitis Obliterans Syndrome (BOS)1
Not AvailableRecruitingSupportive CareBioavailability Study1
Not AvailableRecruitingTreatmentAsthma Bronchial1
Not AvailableRecruitingTreatmentChronic Lung Diseases / Medication Compliance1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis / Chronic Rhinosinusitis Without Polyps / Endoscopic Sinus Surgery / Oral Steroids1
Not AvailableTerminatedTreatmentAsthma Bronchial1
Not AvailableTerminatedTreatmentAsthma Bronchial / Non-Eosinophilic Asthma1
Not AvailableUnknown StatusNot AvailableOesophagitis, Eosinophilic1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableWithdrawnNot AvailableChronic Obstructive Pulmonary Disease (COPD) / Sleep disorders and disturbances1
Not AvailableWithdrawnTreatmentAsthma Bronchial1
Not AvailableWithdrawnTreatmentVitiligo1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Glaxo group ltd dba glaxosmithkline
  • Altana inc
  • G and w laboratories inc
  • Kv pharmaceutical co
  • Perrigo new york inc
  • Tolmar inc
  • Nycomed us inc
  • Taro pharmaceutical industries ltd
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)
PowderOral; Respiratory (inhalation)
PowderRespiratory (inhalation)
Powder, meteredRespiratory (inhalation)113 mcg
Powder, meteredRespiratory (inhalation)232 mcg
Powder, meteredRespiratory (inhalation)55 mcg
Powder, meteredRespiratory (inhalation)
Spray, meteredNasal50 mcg
Powder, meteredRespiratory (inhalation)113 ug/1
Powder, meteredRespiratory (inhalation)232 ug/1
Powder, meteredRespiratory (inhalation)55 ug/1
CreamTopical0.05 %
Spray, meteredNasal
Spray, meteredNasal50 ug/1
Aerosol, metered; suspensionNasal50 mcg
PowderRespiratory (inhalation)100 mcg
PowderRespiratory (inhalation)250 mcg
PowderRespiratory (inhalation)50 mcg
PowderRespiratory (inhalation)500 mcg
Powder, meteredRespiratory (inhalation)100 ug/1
Powder, meteredRespiratory (inhalation)250 ug/1
Powder, meteredRespiratory (inhalation)50 ug/1
Aerosol, meteredOral; Respiratory (inhalation)125 mcg
Aerosol, meteredOral; Respiratory (inhalation)250 mcg
Aerosol, meteredOral; Respiratory (inhalation)50 mcg
Aerosol, meteredRespiratory (inhalation)110 ug/1
Aerosol, meteredRespiratory (inhalation)220 ug/1
Aerosol, meteredRespiratory (inhalation)44 ug/1
Aerosol, meteredOral; Respiratory (inhalation)25 mcg
CreamTopical.5 mg/g
CreamTopical.5 mg/1
LotionTopical.5 mg/mL
OintmentTopical.05 mg/g
Spray, meteredNasal50 ug/.1g
Kit
Kit
Spray, meteredNasal93 ug/1
Prices
Unit descriptionCostUnit
Fluticasone propionate powder1500.0USD g
Cutivate 0.05% Lotion 120ml Bottle454.6USD bottle
Advair Diskus 60 500-50 mcg/dose Aerosol Disp Pack328.14USD disp
Advair Diskus 60 250-50 mcg/dose Aerosol Disp Pack249.48USD disp
Flovent HFA 220 mcg/act Aerosol 12 gm Inhaler237.67USD inhaler
Cutivate 0.05% Cream 60 gm Tube217.11USD tube
Advair Diskus 60 100-50 mcg/dose Aerosol Disp Pack200.79USD disp
Advair Diskus 14 500-50 mcg/dose Aerosol Disp Pack156.64USD disp
Flovent HFA 110 mcg/act Aerosol 12 gm Inhaler153.01USD inhaler
Cutivate 0.005% Ointment 60 gm Tube128.28USD tube
Flovent HFA 44 mcg/act Aerosol 10.6 gm Inhaler114.27USD inhaler
Flovent Diskus 60 50 mcg/blist Aerosol Inhaler104.74USD inhaler
Flonase 50 mcg/act Suspension 16 gm Bottle94.59USD bottle
Fluticasone Propionate 50 mcg/act Suspension 16 gm Bottle78.28USD bottle
Cutivate 0.05% Cream 30 gm Tube62.99USD tube
Fluticasone Propionate 0.005% Ointment 60 gm Tube56.27USD tube
Fluticasone Propionate 0.05% Cream 60 gm Tube56.27USD tube
Cutivate 0.005% Ointment 30 gm Tube44.99USD tube
Fluticasone Propionate 0.005% Ointment 30 gm Tube35.67USD tube
Fluticasone Propionate 0.05% Cream 30 gm Tube35.67USD tube
Cutivate 0.005% Ointment 15 gm Tube32.99USD tube
Cutivate 0.05% Cream 15 gm Tube32.99USD tube
Advair hfa 230-21 mcg inhaler25.04USD g
Fluticasone Propionate 0.005% Ointment 15 gm Tube23.14USD tube
Fluticasone Propionate 0.05% Cream 15 gm Tube23.14USD tube
Advair hfa 115-21 mcg inhaler18.13USD g
Flovent hfa 220 mcg inhaler15.54USD g
Advair hfa 45-21 mcg inhaler14.59USD g
Flovent hfa 110 mcg inhaler12.26USD g
Flovent hfa 44 mcg inhaler10.99USD g
Flonase 0.05% nasal spray5.68USD g
Advair 500-50 diskus5.26USD each
Advair 250-50 diskus4.0USD each
Cutivate 0.05% cream3.48USD g
Advair 100-50 diskus3.22USD each
Flovent 250 mcg diskus2.45USD each
Flovent 100 mcg diskus1.83USD each
Flovent 50 mcg diskus1.74USD each
Flovent Diskus 500 mcg/dose Metered Inhalation Powder1.55USD dose
Flovent Diskus 250 mcg/dose Metered Inhalation Powder0.77USD dose
Flovent Hfa 250 mcg/dose Metered Dose Aerosol0.77USD dose
Flovent Hfa 125 mcg/dose Metered Dose Aerosol0.39USD dose
Flovent Hfa 50 mcg/dose Metered Dose Aerosol0.22USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USRE40045No1993-09-072010-09-07Us
CA2317999No2004-11-092020-09-11Canada
CA2125667No2000-03-132012-12-04Canada
US5873360Yes1996-08-232016-08-23Us
US6446627No1997-12-182017-12-18Us
US6743413Yes2001-12-012021-12-01Us
US6938796Yes1998-07-162018-07-16Us
US6997349Yes1998-07-162018-07-16Us
US6431168Yes1998-12-082018-12-08Us
US7107986Yes1998-12-062018-12-06Us
US7500444Yes2006-08-262026-08-26Us
US6315173Yes1998-06-232018-06-23Us
US7143908Yes1998-07-162018-07-16Us
US6170717Yes1998-06-232018-06-23Us
US7350676Yes1999-02-242019-02-24Us
US7832351Yes2003-12-192023-12-19Us
US6161724Yes1998-07-162018-07-16Us
US6510969Yes1998-06-232018-06-23Us
US6966467Yes1998-06-232018-06-23Us
US6435372Yes1998-07-162018-07-16Us
US7300669No1999-10-202019-10-20Us
US8163723Yes2004-02-292024-02-29Us
US9259428Yes2003-12-132023-12-13Us
US8168620Yes2006-08-242026-08-24Us
US6871646No2001-06-232021-06-23Us
US8978966No2012-01-132032-01-13Us
US6701917No2001-06-232021-06-23Us
US7540282No2003-05-062023-05-06Us
US6748947No2001-06-232021-06-23Us
US8006690No2001-06-232021-06-23Us
US6718972No2001-06-232021-06-23Us
US9216260No2011-06-282031-06-28Us
US8651103No2008-03-262028-03-26Us
US9463288No2005-05-192025-05-19Us
US8714149No2012-02-252032-02-25Us
US9616024No2004-09-012024-09-01Us
US9066957No2014-10-062034-10-06Us
US9415008No2014-10-062034-10-06Us
US9731087No2011-05-182031-05-18Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)272-273 °CNot Available
water solubility0.51 mg/L (insoluble)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0114 mg/mLALOGPS
logP3.69ALOGPS
logP3.72ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity121.65 m3·mol-1ChemAxon
Polarizability49.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9701
Caco-2 permeable+0.5417
P-glycoprotein substrateSubstrate0.7099
P-glycoprotein inhibitor IInhibitor0.7192
P-glycoprotein inhibitor IINon-inhibitor0.8636
Renal organic cation transporterNon-inhibitor0.8689
CYP450 2C9 substrateNon-substrate0.868
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.8988
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.798
CarcinogenicityNon-carcinogens0.8901
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.6125
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dl-0497100000-b64248896abdef386eaf

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androgens and derivatives / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Thioesters / Secondary alcohols / Carbothioic S-esters / Carboxylic acid esters / Cyclic alcohols and derivatives
show 8 more
Substituents
Steroid ester / Androgen-skeleton / Androstane-skeleton / 3-oxosteroid / Hydroxysteroid / 6-halo-steroid / 9-halo-steroid / Oxosteroid / 3-oxo-delta-1,4-steroid / 11-beta-hydroxysteroid
show 28 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
thioester, propanoate ester, 11beta-hydroxy steroid, steroid ester, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid (CHEBI:31441)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Andersson O, Cassel TN, Gronneberg R, Bronnegard M, Stierna P, Nord M: In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma. J Allergy Clin Immunol. 1999 Apr;103(4):595-600. [PubMed:10200007]
  2. Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
  3. Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731]
  4. Hogger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597-602. [PubMed:7878687]
  5. Johnson M: Fluticasone propionate: safety profile. Cutis. 1996 Feb;57(2 Suppl):10-2. [PubMed:8646863]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]
  2. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phospholipase a2 activity
Specific Function
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
Gene Name
PLA2G4A
Uniprot ID
P47712
Uniprot Name
Cytosolic phospholipase A2
Molecular Weight
85238.2 Da
References
  1. Sano A, Munoz NM, Sano H, Choi J, Zhu X, Jacobs B, Leff AR: Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med. 1999 Jun;159(6):1903-9. [PubMed:10351938]
  2. Myo S, Zhu X, Myou S, Meliton AY, Liu J, Boetticher E, Lambertino AT, Xu C, Munoz NM, Leff AR: Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J. 2004 Apr;23(4):511-7. [PubMed:15083746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
  2. Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
  2. Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49